COLLABORATION AND LICENSING AGREEMENTS - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended			3 Months Ended		6 Months Ended			77 Months Ended
	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2024 JPY (¥)	Oct. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2022 USD ($) payment_tranche	Mar. 31, 2018 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 73,222	$ 22,333	$ 119,245		$ 33,702
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				19	764	36		776
Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				599	0	967		0
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				13	3,260	2,139		3,262
2017 KKC Agreement | Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				600		1,000
2017 KKC Agreement | Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				13	3,300	2,100		3,300
Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				0	0	0		0
Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				0	0	0		0
KKC | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees		$ 30,000
Potential development milestones		$ 55,000
Total revenues									$ 35,000
Potential commercialization milestones				52,800		52,800				¥ 8.5
Fee receivable for reduction in royalty rate															$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche															2
KKC | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments												$ 30,000		$ 35,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments				8,000		8,000					$ 3,000		$ 2,000
Upfront payment received	$ 12,000
Potential development and commercialization milestones						$ 113,000
Threshold percentage of net sales for tiered royalties						20.00%	20.00%
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones				700		$ 700
Non-cash royalty revenue																$ 2,300
Potential development and commercialization milestones						16,200	$ 22.2
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue			10.00%
Percentage of non-royalty revenue			20.00%
Maximum potential payment per agreement			$ 75,000
Aggregate cost of revenue recognized				40,200		40,200
Cost of revenue				$ 7,900	$ 1,900	$ 12,600		$ 3,000